Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Quaternary structure of the human Cdt1-Geminin complex regulates DNA replication licensing.

De Marco V, Gillespie PJ, Li A, Karantzelis N, Christodoulou E, Klompmaker R, van Gerwen S, Fish A, Petoukhov MV, Iliou MS, Lygerou Z, Medema RH, Blow JJ, Svergun DI, Taraviras S, Perrakis A.

Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):19807-12. doi: 10.1073/pnas.0905281106. Epub 2009 Nov 11.

2.

P18 is a tumor suppressor gene involved in human medullary thyroid carcinoma and pheochromocytoma development.

van Veelen W, Klompmaker R, Gloerich M, van Gasteren CJ, Kalkhoven E, Berger R, Lips CJ, Medema RH, Höppener JW, Acton DS.

Int J Cancer. 2009 Jan 15;124(2):339-45. doi: 10.1002/ijc.23977.

3.

Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery.

Macůrek L, Lindqvist A, Lim D, Lampson MA, Klompmaker R, Freire R, Clouin C, Taylor SS, Yaffe MB, Medema RH.

Nature. 2008 Sep 4;455(7209):119-23. doi: 10.1038/nature07185. Epub 2008 Jul 9.

PMID:
18615013
4.

Polo-box domains confer target specificity to the Polo-like kinase family.

van de Weerdt BC, Littler DR, Klompmaker R, Huseinovic A, Fish A, Perrakis A, Medema RH.

Biochim Biophys Acta. 2008 Jun;1783(6):1015-22. doi: 10.1016/j.bbamcr.2008.02.019. Epub 2008 Mar 5.

5.

Ablation of the spindle assembly checkpoint by a compound targeting Mps1.

Schmidt M, Budirahardja Y, Klompmaker R, Medema RH.

EMBO Rep. 2005 Sep;6(9):866-72.

6.

Uncoupling anaphase-promoting complex/cyclosome activity from spindle assembly checkpoint control by deregulating polo-like kinase 1.

van de Weerdt BC, van Vugt MA, Lindon C, Kauw JJ, Rozendaal MJ, Klompmaker R, Wolthuis RM, Medema RH.

Mol Cell Biol. 2005 Mar;25(5):2031-44.

7.

Polo-like kinase-1 is required for bipolar spindle formation but is dispensable for anaphase promoting complex/Cdc20 activation and initiation of cytokinesis.

van Vugt MA, van de Weerdt BC, Vader G, Janssen H, Calafat J, Klompmaker R, Wolthuis RM, Medema RH.

J Biol Chem. 2004 Aug 27;279(35):36841-54. Epub 2004 Jun 21.

8.

Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension.

Lens SM, Wolthuis RM, Klompmaker R, Kauw J, Agami R, Brummelkamp T, Kops G, Medema RH.

EMBO J. 2003 Jun 16;22(12):2934-47.

9.

Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D.

Schmidt M, Fernandez de Mattos S, van der Horst A, Klompmaker R, Kops GJ, Lam EW, Burgering BM, Medema RH.

Mol Cell Biol. 2002 Nov;22(22):7842-52.

10.

Inhibition of Polo-like kinase-1 by DNA damage occurs in an ATM- or ATR-dependent fashion.

van Vugt MA, Smits VA, Klompmaker R, Medema RH.

J Biol Chem. 2001 Nov 9;276(45):41656-60. Epub 2001 Aug 20.

11.

Polo-like kinase-1 is a target of the DNA damage checkpoint.

Smits VA, Klompmaker R, Arnaud L, Rijksen G, Nigg EA, Medema RH.

Nat Cell Biol. 2000 Sep;2(9):672-6.

PMID:
10980711
12.

p21 inhibits Thr161 phosphorylation of Cdc2 to enforce the G2 DNA damage checkpoint.

Smits VA, Klompmaker R, Vallenius T, Rijksen G, Mäkela TP, Medema RH.

J Biol Chem. 2000 Sep 29;275(39):30638-43.

13.

Negative growth regulation of SK-N-MC cells by bFGF defines a growth factor-sensitive point in G2.

Smits VA, van Peer MA, Essers MA, Klompmaker R, Rijksen G, Medema RH.

J Biol Chem. 2000 Jun 23;275(25):19375-81.

14.

Inhibition of cell proliferation by lithium is associated with interference in cdc2 activation.

Smits VA, Essers MA, Loomans DS, Klompmaker R, Rijksen G, Medema RH.

FEBS Lett. 1999 Aug 20;457(1):23-7.

15.
16.

CDK-independent activation of estrogen receptor by cyclin D1.

Zwijsen RM, Wientjens E, Klompmaker R, van der Sman J, Bernards R, Michalides RJ.

Cell. 1997 Feb 7;88(3):405-15.

17.

Cyclin D1 triggers autonomous growth of breast cancer cells by governing cell cycle exit.

Zwijsen RM, Klompmaker R, Wientjens EB, Kristel PM, van der Burg B, Michalides RJ.

Mol Cell Biol. 1996 Jun;16(6):2554-60.

18.

A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer.

Michalides R, Hageman P, van Tinteren H, Houben L, Wientjens E, Klompmaker R, Peterse J.

Br J Cancer. 1996 Mar;73(6):728-34.

Supplemental Content

Loading ...
Support Center